Consano Bio
Consano Bio is a clinical-stage biotechnology company advancing a novel therapeutic designed to address serious pain conditions where conventional therapies are limited or ineffective.
Its lead investigational program, C-1101, is being developed as a potential first-in-class, non-opioid pharmaceutical therapy for chronic lumbosacral radiculopathy (LSR), more commonly known as chronic sciatica.
Chronic Sciatica
A chronic lower back pain condition caused by damage or irritation of spinal nerve roots in the lower back, leading to radiating pain from the spine into the legs, numbness, and weakness from the spine into the legs.
C-1101
C-1101 is a novel, multi-protein biologic therapeutic in development as a potential first-in-class, disease-modifying treatment for chronic LSR.